Indoco Remedies Limited (INDOCO.BO)
INR 230.55
(2.28%)
INR 230.55
(2.28%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.74 Billion INR | -27.83% |
| 2022 | 9.03 Billion INR | 13.11% |
| 2021 | 7.98 Billion INR | 13.83% |
| 2020 | 7.01 Billion INR | 0.7% |
| 2019 | 6.96 Billion INR | 10.78% |
| 2018 | 6.28 Billion INR | 4.43% |
| 2017 | 6.02 Billion INR | 0.43% |
| 2016 | 5.99 Billion INR | 10.32% |
| 2015 | 5.43 Billion INR | 34.02% |
| 2014 | 4.05 Billion INR | 9.57% |
| 2013 | 3.7 Billion INR | 24.08% |
| 2012 | 2.98 Billion INR | 15.71% |
| 2011 | 2.57 Billion INR | 48.97% |
| 2010 | 1.73 Billion INR | -3.29% |
| 2009 | 1.78 Billion INR | -37.31% |
| 2008 | 2.85 Billion INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 1.29 Billion INR | -31.17% |
| 2005 | 1.88 Billion INR | 26.07% |
| 2004 | 1.49 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.44 Billion INR | -15.51% |
| 2024 Q2 | 1.62 Billion INR | 12.25% |
| 2023 Q2 | 2.76 Billion INR | 11.94% |
| 2023 Q1 | 2.46 Billion INR | -1.35% |
| 2023 FY | 6.51 Billion INR | -27.83% |
| 2023 Q4 | 1.71 Billion INR | -38.25% |
| 2023 Q3 | 2.77 Billion INR | 0.57% |
| 2022 FY | 9.03 Billion INR | 13.11% |
| 2022 Q1 | 2.11 Billion INR | -7.57% |
| 2022 Q2 | 2.05 Billion INR | -3.02% |
| 2022 Q3 | 2.35 Billion INR | 14.89% |
| 2022 Q4 | 2.5 Billion INR | 6.06% |
| 2021 Q2 | 1.99 Billion INR | -3.31% |
| 2021 Q1 | 2.06 Billion INR | 29.72% |
| 2021 FY | 7.98 Billion INR | 13.83% |
| 2021 Q3 | 1.85 Billion INR | -6.85% |
| 2021 Q4 | 2.29 Billion INR | 23.22% |
| 2020 FY | 7.01 Billion INR | 0.7% |
| 2020 Q1 | 1.55 Billion INR | -11.1% |
| 2020 Q4 | 1.59 Billion INR | -18.8% |
| 2020 Q3 | 1.96 Billion INR | 2.79% |
| 2020 Q2 | 1.9 Billion INR | 22.5% |
| 2019 FY | 6.96 Billion INR | 10.78% |
| 2019 Q3 | 1.83 Billion INR | 0.73% |
| 2019 Q1 | 1.56 Billion INR | -6.53% |
| 2019 Q4 | 1.75 Billion INR | -4.51% |
| 2019 Q2 | 1.82 Billion INR | 16.58% |
| 2018 Q3 | 1.52 Billion INR | -5.74% |
| 2018 Q1 | 1.46 Billion INR | 0.0% |
| 2018 FY | 6.28 Billion INR | 4.43% |
| 2018 Q4 | 1.67 Billion INR | 9.29% |
| 2018 Q2 | 1.62 Billion INR | 10.47% |
| 2017 FY | 6.02 Billion INR | 0.43% |
| 2016 FY | 5.99 Billion INR | 10.32% |
| 2015 FY | 5.43 Billion INR | 34.02% |
| 2014 Q1 | 983.4 Million INR | 0.0% |
| 2014 FY | 4.05 Billion INR | 9.57% |
| 2013 Q1 | 770.7 Million INR | 19.68% |
| 2013 FY | 3.7 Billion INR | 24.08% |
| 2012 Q4 | 643.97 Million INR | 0.0% |
| 2012 FY | 2.98 Billion INR | 15.71% |
| 2011 FY | 2.57 Billion INR | 48.97% |
| 2010 FY | 1.73 Billion INR | -3.29% |
| 2009 FY | 1.78 Billion INR | -37.31% |
| 2008 FY | 2.85 Billion INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | 1.29 Billion INR | -31.17% |
| 2005 FY | 1.88 Billion INR | 26.07% |
| 2004 FY | 1.49 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 96.92% |
| NATCO Pharma Limited | 10.05 Billion INR | 52.786% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -238.524% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -403.902% |
| Achyut Healthcare Limited | 1.6 Million INR | -295038.098% |
| Ajanta Pharma Limited | 30.46 Billion INR | 84.411% |
| Alkem Laboratories Limited | 32.83 Billion INR | 85.537% |
| Alpa Laboratories Limited | 156.14 Million INR | -2941.219% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 70.076% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -82.617% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 87.897% |
| Bajaj HealthCare Limited | 985.34 Million INR | -381.94% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -234.604% |
| Brooks Laboratories Limited | 51.18 Million INR | -9178.57% |
| Divi's Laboratories Limited | 14.17 Billion INR | 66.487% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 95.047% |
| Eris Lifesciences Limited | 4.94 Billion INR | 3.928% |
| FDC Limited | 5.34 Billion INR | 11.213% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 92.971% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 59.205% |
| Granules India Limited | 7.18 Billion INR | 33.883% |
| Gufic Biosciences Limited | 1.07 Billion INR | -340.635% |
| Hester Biosciences Limited | 908.84 Million INR | -422.509% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -123.557% |
| Ipca Laboratories Limited | 13.91 Billion INR | 65.873% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -514.004% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -10188.526% |
| Lasa Supergenerics Limited | 291.17 Million INR | -1530.905% |
| Laurus Labs Limited | 3.01 Billion INR | -57.725% |
| Lupin Limited | 95.67 Billion INR | 95.036% |
| Mankind Pharma Limited | 23.15 Billion INR | 79.489% |
| Medicamen Biotech Limited | 335.16 Million INR | -1316.838% |
| Medico Remedies Limited | 161.84 Million INR | -2834.166% |
| Megasoft Limited | 49.52 Million INR | -9488.055% |
| Piramal Pharma Limited | 19.91 Billion INR | 76.154% |
| RPG Life Sciences Limited | 1.63 Billion INR | -190.356% |
| Sigachi Industries Limited | 579.88 Million INR | -718.913% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -54.341% |
| Unichem Laboratories Limited | 6.72 Billion INR | 29.395% |
| Wanbury Limited | 1.16 Billion INR | -309.05% |
| Windlas Biotech Limited | 1 Billion INR | -371.806% |
| ZIM Laboratories Limited | 1.01 Billion INR | -368.756% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 89.001% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -58.535% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -332.104% |
| Bal Pharma Limited | 389.89 Million INR | -1117.977% |
| Strides Pharma Science Limited | 9.16 Billion INR | 48.171% |
| Venus Remedies Limited | 1.91 Billion INR | -147.811% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -54.462% |
| Nectar Lifesciences Limited | 625.55 Million INR | -659.135% |
| Shilpa Medicare Limited | 2.18 Billion INR | -117.775% |
| Aarti Drugs Limited | 1.16 Billion INR | -306.754% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -332.178% |
| Suven Life Sciences Limited | 109.75 Million INR | -4226.899% |
| Ind-Swift Limited | 946.56 Million INR | -401.684% |
| Valiant Laboratories Limited | 36.28 Million INR | -12985.982% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 43.582% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -3.692% |
| Themis Medicare Limited | 782.85 Million INR | -506.597% |
| Hikal Limited | 2.48 Billion INR | -90.994% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 77.832% |
| Sequent Scientific Limited | 2.9 Billion INR | -63.649% |
| Novartis India Limited | 470.1 Million INR | -910.162% |
| Wockhardt Limited | 6.4 Billion INR | 25.8% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 67.146% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -29195.868% |
| Neuland Laboratories Limited | 2.92 Billion INR | -62.088% |
| Morepen Laboratories Limited | 1.98 Billion INR | -138.938% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -1051.421% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -602.328% |